SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026
WW

WWB

Qiming Venture Partners
BULLISH
Impact 5/10
Horizonweeks Processed3d 1h ago WireGlobeNewswire
Press release · IPO
Actionable Insight ▲ Bullish

Monitor Windward Bio's upcoming clinical data readouts for WIN378 (POLARIS-1 Phase 2/3 in asthma, SIRIUS Phase 2 in COPD) as key catalysts. Qiming's continued participation in the IPO signals long-term commitment.

DirectionBullish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Qiming Venture Partners' portfolio company Windward Bio (WWB) listed on Nasdaq at $17.00 per share, closing at $28.50 on its first day for a market cap of approximately $1.69 billion. Qiming participated in the IPO financing round and had previously invested in Windward Bio's Series A and Series B rounds.

Key Facts

  • Windward Bio (WWB) priced its IPO at $17.00 per share
  • Shares closed at $28.50 on first trading day, up 68% from IPO price
  • Market capitalization approximately $1.69 billion
  • Qiming Venture Partners participated in IPO financing round
  • Windward Bio's lead program WIN378 is in Phase 2/3 for severe asthma and Phase 2 for COPD
  • Windward Bio holds exclusive global rights (excluding Greater China and certain Asian countries) to WIN378 via licensing from Kelun-Biotech and Harbour BioMed
  • Windward Bio licensed WIN027 from Qyuns Therapeutics

Financial Impact

IPO raised undisclosed amount at $17.00 per share; first-day close at $28.50 implies a market cap of ~$1.69 billion

market capitalizationvaluation

Risk Factors

  • Windward Bio is a clinical-stage company with no approved products
  • WIN378 and WIN027 are in early-to-mid-stage clinical trials; regulatory and commercial risks remain
  • Licensing agreements with Kelun-Biotech, Harbour BioMed, and Qyuns Therapeutics introduce counterparty and territorial restrictions

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302939481

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026